Form D · Biotechnology
NextRNA Therapeutics, Inc.
Cambridge, MA · CIK 0001907060
Offering snapshot reported Jan 27, 2022 · SEC filing
- Reported sold
- $23.4M Offering amount: $50M
- Investors reported
- 34 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 12, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 27, 2022 | Initial | $23,379,003 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-431048
Source: Form D, filed Jan 27, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth Anderson | Director |
| Andrea Armstrong | Director |
| Arthur Becker | Director |
| Alain Cohen | Director |
| Marc A. Cohen | Director, Executive |
| Drew Dennison | Director |
| Christine Henderson | Director |
| Susan Langer | Director |
| Fred Mermelstein | Director |
| Julia A. Novina | Executive |
| Carl Novina | Director |
| Barry Polisky | Director |
| Elena Prokupets | Director |
| Malcolm Salter | Director |
| Dominique Verhelle | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Ipsen Biolabs 650 E. Kendall Street
Cambridge, MA, 02142
Cambridge, MA, 02142